The LumiraDx SARS-CoV-2 Ag Quality Controls (QC) are liquid quality controls used with the LumiraDx Instrument and the LumiraDx SARS-CoV-2 Ag Test. When transferring the QC material from the vial to the Test Strip, a transfer pipette is used.

Please be advised that the following transfer pipettes are acceptable for use with the LumiraDx SARS-CoV-2 Ag QC material:

- 20µL Dual-Bulb Plastic Transfer Pipettes (single use)
- 20µL Single-Bulb Plastic Transfer Pipettes (single use)
- Calibrated Laboratory Pipette (set to 20µL with appropriate tips)

Please note that any transfer pipettes used with the LumiraDx SARS-CoV-2 Ag QC material should never contain any coatings, additives, surfactants or preservatives.

For product inquiries and technical support please contact LumiraDx Technical Support.

**US**
- Email: customerservices.US@lumiradx.com
- Telephone: 1-888-586-4721
- www.lumiradx.com

**International**
- Email: customerservices@lumiradx.com
- Telephone: +44 (0)1172841222
- www.lumiradx.com

Supplemental Instructions

**Transfer Pipette Configuration**

- **20µL Dual-Bulb Plastic Transfer Pipettes** (single use)
- **20µL Single-Bulb Plastic Transfer Pipettes** (single use)
- **Calibrated Laboratory Pipette** (set to 20µL with appropriate tips)

Note: the tip of the pipette will be tapered.

- Squeeze the bulb, drawing up QC material into the pipette.
- Hold the pipette over the sample application area of the Test Strip and squeeze the upper bulb for a second time to dispense 20µL of QC material on to the Test Strip.

- Ensure no air bubbles are present within the pipette tip and that the whole tip of the pipette is filled with QC material.
- Hold the pipette over the sample application area of the Test Strip and squeeze the upper bulb for a second time to dispense 20µL of QC material on to the Test Strip.

- Follow the applicable manufacturer’s recommendations for correctly dispensing exactly 20µL of QC material to the Test Strip.

Manufactured by:
- LumiraDx UK Ltd
- Dumyat Business Park
- Alloa
- FK10 2PB, UK
- Registration Number: 09206123

Authorized representative in the European Union:
- LumiraDx AB
- Västra Vägen 5A
- 16961 Solna, Sweden

US Office:
- LumiraDx
- 221 Crescent Street
- Suite 502
- Waltham
- Massachusetts 02453
- USA

Copyright © 2021 LumiraDx UK LTD. All rights reserved worldwide. LumiraDx and Flame logo are trademarks of LumiraDx International LTD. Full details of these and other registrations of LumiraDx can be found at lumiradx.com/IF. All other trademarks are the property of their respective owners. Content should be used for the use of the LumiraDx products only and in line with instructions provided. You may not, except with our express written permission, distribute or commercially exploit the content. Nor may you transmit it or store it in any other form of electronic retrieval system other than for the purpose of use of the LumiraDx Instrument or LumiraDx Test Strips. Information provided is subject to change without notice.

Product is not available in all countries and regions. Please check with your local LumiraDx sales representative or distributor for availability in specific markets. Available in the USA under FDA Emergency Use Authorization.

In the USA, this test has not been FDA cleared or approved; this test has been authorized by FDA under an EUA for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. This test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. In the USA, this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.